– ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net product revenue raised to $670 – $675 million –– KPL-387 granted Orphan Drug Designation for the treatment of pericarditis – – Cash balance increased by $44.3 million in Q3 2025 to $352.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Oct. 28, 2025 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported third quarter 2025 financial results and recent portfolio execution. “Year to date, ARCALYST revenue has continued to grow, with the expanding adoption of IL-1α...

Continued Strong Orders and Revenue Growth Headline Multiple Performance Records Reaffirms 2025 Full Year Outlook and Introduces 2026 Outlook ADDISON, Texas, Oct. 28, 2025 (GLOBE NEWSWIRE) — CECO Environmental Corp. (Nasdaq: CECO) (“CECO” or the “Company”), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment, and industrial equipment, today reported its financial results for the third quarter of 2025. Third Quarter Summary(1)Orders of $232.9 million, up 44 percent Backlog of $719.6 million, up 64 percent Revenue of $197.6 million, up 46 percent Gross profit margin of 32.7 percent; Gross profit of $64.6 million, up 43 percent Net income of $1.5 million; non-GAAP net income of $9.3 million GAAP EPS (diluted) of $0.04; non-GAAP EPS (diluted) of...

Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 27% to $4.86 billion EYLEA HD® U.S. net sales increased 10% to $431 million; total EYLEA HD and EYLEA® U.S. net sales decreased 28% to $1.11 billion GAAP EPS of $13.62 and non-GAAP EPS(a) of $11.83; third quarter 2025 includes unfavorable $0.68 impact from acquired IPR&D charge FDA approved Libtayo® as the first and only immunotherapy for high-risk adjuvant cutaneous squamous cell carcinoma (CSCC); EMA’s CHMP adopted positive opinion Positive Phase 3 results reported from trials in generalized myasthenia gravis, fibrodysplasia ossificans progressiva (FOP), and cat and birch allergies; updated positive data reported from pivotal trial in children with profound genetic hearing lossTARRYTOWN,...

Strong Demand Drives 20 Percent Calculated Billings Growth Year Over Year TEL AVIV, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) — Check Point® Software Technologies Ltd. (NASDAQ: CHKP), today announced its financial results for the quarter ended September 30th, 2025. Third Quarter 2025 Financial Highlights:Calculated Billings*: $672 million, a 20 percent increase year over year Total Revenues: $678 million, a 7 percent increase year over year Security Subscriptions Revenues: $305 million, a 10 percent increase year over year GAAP Operating Income: $199 million, representing 29 percent of total revenues Non-GAAP Operating Income: $282 million, representing 42 percent of total revenues GAAP EPS**: $3.28, a 79 percent increase year over year Non-GAAP EPS**: $3.94, a 75 percent increase year over year“Check Point delivered strong third...

PHILADELPHIA, Oct. 28, 2025 (GLOBE NEWSWIRE) — Axalta Coating Systems Ltd. (NYSE:AXTA) (“Axalta”), a leading global coatings company, announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights:Third quarter net sales of approximately $1.3 billion Net income of $110 million with a net income margin of 8.5%, an increase of 80 basis points year over year Record quarter for Adjusted EBITDA of $294 million Adjusted EBITDA margin expanded 70 basis points year over year to 22.8% Diluted EPS increased 11% to $0.51 Record quarter for Adjusted Diluted EPS of $0.67, an increase of 6% Executed $100 million in share repurchases“We executed another strong quarter delivering record Adjusted EBITDA and Adjusted Diluted EPS. Our results reflect our focus on operational excellence while the...

Net Income of $1.68 million in the September 2025 Quarter, Up 3% from the Sequential Quarter and Down 12% from the Comparable Quarter Last Year  Net Interest Margin of 3.00% in the September 2025 Quarter, Up Six Basis Points from the Sequential Quarter and Up 16 Basis Points from the Comparable Quarter Last Year Loans Held for Investment of $1.04 Billion at September 30, 2025, Down Slightly from $1.05 Billion at June 30, 2025 Total Deposits of $874.8 Million at September 30, 2025, Down 2% from June 30, 2025 Non-Performing Assets to Total Assets Ratio of 0.15% at September 30, 2025, Up from 0.11% at June 30, 2025 RIVERSIDE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) — Provident Financial Holdings, Inc. (“Company”), NASDAQ GS: PROV, the holding company for Provident Savings Bank, F.S.B. (“Bank”), today announced earnings for the first...

ORION CORPORATION INTERIM REPORT 1–9/2025 28 OCTOBER 2025 at 12:00 EET Orion Group Interim Report January–September 2025 July–September 2025 HighlightsNet sales totalled EUR 423.2 (July–September 2024: 471.3) million Operating profit was EUR 121.0 (202.0) million Net sales and operating profit of the comparison period include EUR 130 million of major milestone payments Basic earnings per share were EUR 0.68 (1.14) Cash flow from operating activities per share was EUR 0.55 (0.48) The outlook for 2025 has been specified: Net sales are estimated to be EUR 1,640 million to EUR 1,720 million. Operating profit is estimated to be EUR 410 million to EUR 490 million. Previously net sales were estimated to be EUR 1,630 million to EUR 1,730 million and operating profit was estimated to be EUR 400 million to EUR 500 million.January–September...

Statkraft will disclose the third quarter results for 2025 on Thursday 30 October 2025 at 08:00 a.m. CET. The documents will be available on Statkraft’s website www.statkraft.com and Oslo Stock Exchange’s news service www.newsweb.no. WebcastAt 09:30 a.m. CEST, Statkraft will present the results via webcast at www.statkraft.com. The presentation will be held in English. Contact: Arild Ratikainen, Investor Contact, tlf.: +47 971 74 132, e-mail: arild.ratikainen@statkraft.com

SMITHFIELD, Va., Oct. 28, 2025 (GLOBE NEWSWIRE) — Smithfield Foods, Inc. (Nasdaq: SFD), an American food company and an industry leader in value-added packaged meats and fresh pork, today reported results for its fiscal 2025 third quarter ended September 28, 2025. Third Quarter Fiscal 2025 Financial HighlightsNet sales of $3.7 billion, up 12.4% from the third quarter of 2024 Operating profit and adjusted operating profit of $310 million Operating margin and adjusted operating margin of 8.3% Packaged Meats operating profit and adjusted operating profit of $226 million; operating profit margin and adjusted operating profit margin of 10.8% Diluted earnings per share from continuing operations attributable to Smithfield of $0.63 per share Adjusted diluted earnings per share from continuing operations attributable to Smithfield of...

OP Mortgage BankInterim Report 1 January–30 September 2025Stock Exchange Release 28 October 2025 at 10.00 EET OP Mortgage Bank: Interim Report 1 January–30 September 2025 OP Mortgage Bank (OP MB) is the covered bond issuing entity of OP Pohjola. Together with OP Corporate Bank plc, its role is to raise funding for OP Pohjola from money and capital markets. OP Financial Group changed its name to OP Pohjola on 28 October 2025. Financial standing Bonds issued by OP MB totalled EUR 14,800 million (14,800)* at the end of September. All funds received from the bonds have been intermediated in their entirety to 60 OP cooperative banks in the form of intermediary loans. OP MB’s covered bonds after 8 July 2022 are issued under the Euro Medium Term Covered Bond (Premium) programme (EMTCB), pursuant to the Finnish Act on Mortgage Credit Banks...